These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 15785941

  • 1. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB.
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ.
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F, Corradi B, Imbasciati E.
    Adv Perit Dial; 1996 Jun; 12():239-44. PubMed ID: 8865912
    [Abstract] [Full Text] [Related]

  • 8. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Jun; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 9. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S, Akizawa T, Kurokawa K, Marumo F, Sakai O, Arakawa M, Morii H, Seino Y, Ogata E, Ohashi Y, Akiba T, Tsukamoto Y, Suzuki M.
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [Abstract] [Full Text] [Related]

  • 10. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G, Schmitt CP, Bianchi ML, Daccò V, Claris-Appiani A, Mehls O.
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [Abstract] [Full Text] [Related]

  • 11. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
    Grekas D, Balaskas E, Kampouris H, Benos A, Konstantinou A, Sioullis A, Tourkantonis A.
    Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA.
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E.
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [Abstract] [Full Text] [Related]

  • 18. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
    Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK.
    Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
    Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB.
    Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.